Clinical Trials
158 trialsAZUR-1
GlaxoSmithKline
EVEREST-2
A2 Biotherapeutics Inc.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
KANDLELIT-012
Merck Sharp & Dohme LLC
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
AMPLIFY-7P
Elicio Therapeutics
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
COMPANION-003
Compass Therapeutics
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen Inc.
KRYSTAL-10
Mirati Therapeutics Inc.
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
SEAMARK
Pfizer
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
SECURE
Medtronic - MITG
DEL-LIVER
Delcath Systems Inc.
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
ColoSealâ„¢ ICD System Anastomotic Protection Pivotal Study
Averto Medical, Inc.
SYLVER
GlaxoSmithKline
SCORE
Natera, Inc.
INJECTABL-3
Immunophotonics, Inc.
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
VARTUTRACE
Var2 Pharmaceuticals
PREEMPT CRC
Freenome Holdings Inc.
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
China AZUR-1
GlaxoSmithKline
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Efficacy and Safety of the CG-100 Intraluminal Bypass Device
Colospan Ltd.
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
xDRIVE in Metastatic Colorectal Cancer
First Ascent Biomedical Inc.
DENALI-1
A2 Biotherapeutics Inc.
AMPLIFY-201
Elicio Therapeutics
ORACLE
Guardant Health, Inc.
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
SAFE-2
SafeHeal Inc
CEA+RC-BCG
Medicine Invention Design, Inc
Bovine Reinforcement in Stomach, Colorectal and Lung Operation
Shanghai Cingularbio Co. Ltd
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
MINIGO
Qufora A/S
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
GILongevity
KISIMA-01
Amal Therapeutics
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
Viome
ROOT
Taproot Health
Validation of a Molecular Signature for Early Detection of Colorectal Cancer
ADVANCED MARKER DISCOVERY S.L.
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Hutchmed
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
Gene Solutions
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NantBioScience, Inc.